It is reported that patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease (NFALD) were treated with aggliptin for 12 months, and the scores of nonalcoholic fatty hepatitis (NASH), ferritin, insulin and collagen IV 7S were significantly improved [11]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.